Keyphrases
Bevacizumab
100%
Glioblastoma
84%
Recurrent Glioblastoma
83%
Overall Survival
65%
Progression-free Survival
31%
Irinotecan
30%
Tyrosine
26%
Angiotensinogen
25%
Prognostic Model
25%
Bevacizumab Therapy
22%
Bevacizumab Treatment
22%
Combination Therapy
21%
Tumor
18%
Glioma Patients
17%
Newly Diagnosed Glioblastoma
17%
Targeted Therapy
17%
18F-fluoro-ethyl-tyrosine
17%
Diagnostic Accuracy
17%
Molecular Profiling
17%
Human Glioblastoma
17%
Multivariate Analysis
17%
Prognostic Biomarker
14%
Relative Tumor Volume
13%
Promoter Methylation
13%
Prognostic Value
13%
Non-responders
13%
Predictive Biomarker
12%
Quality of Life
12%
Magnetic Resonance Imaging
12%
Prognostic Factors
12%
Methylation Status
12%
Tumor Tissue
12%
Glioblastoma multiforme
11%
Response Rate
11%
DNA Methylation (DNAm)
11%
Treatment Response
10%
PET Scan
10%
Radiation Therapy
9%
Hazard Rate
8%
Epid
8%
Comprehensive Profile
8%
Advanced Adrenocortical Carcinoma
8%
Multimodal Strategy
8%
Residual Tumor
8%
Grade III Gliomas
8%
Diffuse Midline Glioma H3 K27M-mutant
8%
ATRX mutation
8%
Micro-MRI
8%
Orthotopic Model
8%
NF2-related Schwannomatosis
8%
Medicine and Dentistry
Glioblastoma
73%
Bevacizumab
45%
Overall Survival
36%
Neoplasm
35%
Ganglioglioma
28%
Progression Free Survival
22%
Biological Marker
19%
Targeted Therapy
17%
Irinotecan
17%
Fluorine-18
17%
Magnetic Resonance Imaging
17%
Prognostic Factor
11%
Multivariate Analysis
11%
Positron Emission Tomography
10%
Vasculotropin
10%
Positron Emission Tomography
10%
Systematic Review
8%
Vasculotropin C
8%
Schwannomatosis
8%
Radiological Finding
8%
Vestibular Schwannoma
8%
Diagnostic Accuracy
8%
Vasculotropin Receptor 2
8%
Quality of Life
8%
Placental Growth Factor
8%
Radiation Therapy Planning
8%
Protein P53
7%
Cancer
6%
Radiation Therapy
6%
Proportional Hazards Model
6%
Surgery
5%